{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:10:15Z","timestamp":1776798615422,"version":"3.51.2"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Resistant chronic migraine is a highly disabling condition which is very difficult to treat. The majority of the treatments for migraine prophylaxis are nonspecific and present weak safety profiles, leading to low adherence and discontinuation. Currently, monoclonal antibodies (mAb) targeting the trigeminal sensory neuropeptide, calcitonin gene-related peptide (CGRP), are available for migraine prophylaxis being the first drugs developed specifically to target migraine pathogenesis. The main objective of the current work is to carry out a systematic review of randomised controlled trials that specifically analyse the effectivity and safety of anti-CGRP mAb, comparatively to placebo, in patients with resistant chronic migraine and possibly fill the literature gap or be a source of information to health professionals. Additionally the current knowledge on migraine, particularly resistant chronic migraine, was revisited and summarised.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Literature search was carried out on MEDLINE, Scopus, Science Direct and ClinicalTrials.gov database, from inception to December 2021. Articles were selected according to prespecified criteria of inclusion and exclusion. Efficacy and safety outcomes included were: change from baseline in monthly migraine days (MMD); \u226550% reduction of MMD values from baseline; change from baseline in monthly acute migraine-specific medication days (MAMD); Migraine-specific Quality of Life Questionnaire (MSQ); and registered adverse events. Additionally, we used the Cochrane risk of bias tool (RoB 2) to assess the risk of bias of the included studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four studies were included in this systematic review, involving 2811 resistant chronic migraine patients, 667 in a study using erenumab, 838 in a study using fremanezumab and 1306 in two studies using galcanezumab. When compared to placebo, all investigated anti-CGRP mAb and respective doses demonstrate effectiveness in decreasing MMD, reducing acute medication use and improving the MSQ scores, including, sometimes, reversion of chronic to episodic migraine (efficacy outcomes). Regarding the safety outcomes, the number and type of adverse events did not differ between anti-CGRP mAb-treated and placebo groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Anti-CGRP or anti-CGRP receptor monoclonal antibodies are a promising preventive migraine therapy which can be particularly useful for resistant chronic migraine patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-022-00716-w","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T16:02:34Z","timestamp":1654358554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-7085","authenticated-orcid":false,"given":"Hugo","family":"Sevivas","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-7798","authenticated-orcid":false,"given":"Paula","family":"Fresco","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"issue":"10127","key":"716_CR1","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","volume":"391","author":"DW Dodick","year":"2018","unstructured":"Dodick DW. Migraine. Lancet. 2018;391(10127):1315\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(18)30478-1.","journal-title":"Lancet"},{"issue":"7","key":"716_CR2","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1177\/1359105312446773","volume":"18","author":"M Mollao\u011flu","year":"2013","unstructured":"Mollao\u011flu M. Trigger factors in migraine patients. J Health Psychol. 2013;18(7):984\u201394. https:\/\/doi.org\/10.1177\/1359105312446773.","journal-title":"J Health Psychol"},{"issue":"5","key":"716_CR3","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00415-020-10344-1","volume":"268","author":"N Karsan","year":"2021","unstructured":"Karsan N, Bose P, Newman J, Goadsby PJ. Are some patient-perceived migraine triggers simply early manifestations of the attack? J Neurol. 2021;268(5):1885\u201393. https:\/\/doi.org\/10.1007\/s00415-020-10344-1.","journal-title":"J Neurol"},{"key":"716_CR4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"T Vos","year":"2017","unstructured":"Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1211\u201359.","journal-title":"Lancet"},{"key":"716_CR5","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17:954\u201376.","journal-title":"Lancet Neurol"},{"key":"716_CR6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/j.1468-2982.2008.01666.x","volume":"28","author":"WF Stewart","year":"2008","unstructured":"Stewart WF, Wood C, Reed ML, Roy J, Lipton RB. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008;28:1170\u20138.","journal-title":"Cephalalgia"},{"key":"716_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European headache federation and lifting the burden: the global campaign against headache. J Headache Pain. 2019;20:57.","journal-title":"J Headache Pain"},{"key":"716_CR8","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211.","DOI":"10.1177\/0333102417738202"},{"key":"716_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","volume":"18","author":"M Ashina","year":"2019","unstructured":"Ashina M, Hansen JM, Do TP, MeloCarrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system\u201340 years and counting. Lancet Neurol. 2019;18:795\u2013804.","journal-title":"Lancet Neurol"},{"key":"716_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/ana.410160202","volume":"16","author":"MA Moskowitz","year":"1984","unstructured":"Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984;16:157\u201368.","journal-title":"Ann Neurol"},{"key":"716_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S1474-4422(09)70090-0","volume":"8","author":"J Olesen","year":"2009","unstructured":"Olesen J, Burstein R, Ashina M, TfeltHansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol. 2009;8:679\u201390.","journal-title":"Lancet Neurol"},{"key":"716_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1468-2982.2007.01303.x","volume":"27","author":"L Kelman","year":"2007","unstructured":"Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27:394\u2013402.","journal-title":"Cephalalgia"},{"key":"716_CR13","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/head.12464","volume":"54","author":"RB Lipton","year":"2014","unstructured":"Lipton RB, Pavlovic JM, Haut SR, Grosberg BM, Buse DC. Methodological issues in studying trigger factors and premonitory features of migraine. Headache. 2014;54:1661\u20139.","journal-title":"Headache"},{"key":"716_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1212\/WNL.0b013e31827f0f10","volume":"80","author":"A Hougaard","year":"2013","unstructured":"Hougaard A, Amin FM, Hauge AW, Ashina M, Olesen J. Provocation of migraine with aura using natural trigger factors. Neurology. 2013;80:428\u201331.","journal-title":"Neurology"},{"key":"716_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrneurol.2017.137","volume":"13","author":"M Ashina","year":"2017","unstructured":"Ashina M, Hansen JM, Dunga \u00c1B, BO, Olesen J. Human models of migraine-short-term pain for long-term gain. Nat Rev Neurol. 2017;13:713\u201324.","journal-title":"Nat Rev Neurol"},{"key":"716_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1468-1331.1994.tb00053.x","volume":"1","author":"LL Thomsen","year":"1994","unstructured":"Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol. 1994;1:73\u201380.","journal-title":"Eur J Neurol"},{"key":"716_CR17","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0333102410368444","volume":"30","author":"JM Hansen","year":"2010","unstructured":"Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30:1179\u201386.","journal-title":"Cephalalgia"},{"key":"716_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/brain\/awn307","volume":"132","author":"HW Schytz","year":"2009","unstructured":"Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009;132:16\u201325.","journal-title":"Brain"},{"key":"716_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54\u201361.","journal-title":"Cephalalgia"},{"key":"716_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.pain.2003.09.008","volume":"106","author":"G Juhasz","year":"2003","unstructured":"Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106:461\u201370.","journal-title":"Pain"},{"issue":"6","key":"716_CR21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/j.1526-4610.2008.01132.x","volume":"48","author":"EA Schulman","year":"2008","unstructured":"Schulman EA, Lake AE 3rd, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG, Lipton RB. Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American Headache Society. Headache. 2008;48(6):778\u201382. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01132.x.","journal-title":"Headache"},{"key":"716_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/1744806918767697","author":"M Su","year":"2018","unstructured":"Su M, Yu S. Chronic migraine: a process of dysmodulation and sensitization. Mol Pain. 2018. https:\/\/doi.org\/10.1177\/1744806918767697.","journal-title":"Mol Pain"},{"issue":"8","key":"716_CR23","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/head.12642","volume":"55","author":"S Silberstein","year":"2015","unstructured":"Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what headache specialists need to know. Headache. 2015;55(8):1171\u201382. https:\/\/doi.org\/10.1111\/head.12642.","journal-title":"Headache"},{"key":"716_CR24","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.2147\/JPR.S128143","volume":"10","author":"MA Giamberardino","year":"2017","unstructured":"Giamberardino MA, Affaitati G, Costantini R, Cipollone F, Martelletti P. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. J Pain Res. 2017;10:2751\u201360.","journal-title":"J Pain Res"},{"key":"716_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40263-015-0253-z","volume":"29","author":"S Wrobel Goldberg","year":"2015","unstructured":"Wrobel Goldberg S, Silberstein SD. Targeting CGRP: a new era for migraine treatment. CNS Drugs. 2015;29:443\u201352.","journal-title":"CNS Drugs"},{"key":"716_CR26","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1177\/0333102414527646","volume":"34","author":"ME Bigal","year":"2014","unstructured":"Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014;34:968\u201376.","journal-title":"Cephalalgia"},{"issue":"8","key":"716_CR27","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","volume":"48","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157\u201368.","journal-title":"Headache"},{"key":"716_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/head.13459","author":"DC Buse","year":"2018","unstructured":"Buse DC, Greisman JD, Baigi K, et al. Migraine progression: a systematic review. Headache. 2018. https:\/\/doi.org\/10.1111\/head.13459.","journal-title":"Headache"},{"issue":"7","key":"716_CR29","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.pain.2014.03.001","volume":"155","author":"N Boyer","year":"2014","unstructured":"Boyer N, Dallel R, Artola A, et al. General trigeminospinal central sensitization and impaired descending pain inhibitory controls contribute to migraine progression. Pain. 2014;155(7):1196\u2013205.","journal-title":"Pain"},{"issue":"4","key":"716_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10194-012-0447-4","volume":"13","author":"Y-C Chen","year":"2012","unstructured":"Chen Y-C, Tang C-H, Ng K, et al. Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan. J Headache Pain. 2012;13(4):311\u20139.","journal-title":"J Headache Pain"},{"issue":"4","key":"716_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"716_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0333102414552532","volume":"35","author":"AM Adams","year":"2015","unstructured":"Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) study methods and baseline results. Cephalalgia. 2015;35(7):563\u201378.","journal-title":"Cephalalgia"},{"issue":"7","key":"716_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","volume":"87","author":"MT Minen","year":"2016","unstructured":"Minen MT, Begasse De Dhaem O, Kroon Van Diest A, et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):741\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"7","key":"716_CR34","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/j.1526-4610.2011.01945.x","volume":"51","author":"M Stokes","year":"2011","unstructured":"Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011;51(7):1058\u201377.","journal-title":"Headache"},{"key":"716_CR35","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1007\/s10072-010-0269-6","volume":"31","author":"P Barbanti","year":"2010","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L. Hypertension as a risk factor for migraine chronification. Neurol Sci. 2010;31:S41\u20133. https:\/\/doi.org\/10.1007\/s10072-010-0269-6.","journal-title":"Neurol Sci"},{"key":"716_CR36","first-page":"145","volume":"8","author":"M Bigal","year":"2009","unstructured":"Bigal M. Migraine chronification\u2014concept and risk factors. Discov Med. 2009;8:145\u201350.","journal-title":"Discov Med"},{"issue":"1","key":"716_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11916-010-0157-z","volume":"15","author":"AN Manack","year":"2011","unstructured":"Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011 Feb;15(1):70-8.","journal-title":"Curr Pain Headache Rep."},{"key":"716_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1129-2377-15-47","volume":"15","author":"P Martelletti","year":"2014","unstructured":"Martelletti P, Katsarava Z, Lampi C, Magis D, Bendtsen L, Negro A, et al. Refractory chronic migraine: a consensus statement on clinical definition from the European headache federation. J Headache Pain. 2014;15:47\u201356.","journal-title":"J Headache Pain"},{"key":"716_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine. J Headache Pain. 2020;21:76.","journal-title":"J Headache Pain"},{"issue":"2","key":"716_CR40","doi-asserted-by":"publisher","first-page":"01215","DOI":"10.1002\/brb3.1215","volume":"9","author":"L Han","year":"2019","unstructured":"Han L, Liu Y, Xiong H, Hong P. CGRP monoclonal antibody for preventive treatment of chronic migraine: an update of meta-analysis. Brain Behav. 2019;9(2):01215.","journal-title":"Brain Behav"},{"issue":"14","key":"716_CR41","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.3390\/ijms20143527","volume":"20","author":"I Huang","year":"2019","unstructured":"Huang I, Wu P-C, Lin E-Y, Chen C-Y, Kang Y-N. Effects of anti-calcitonin gene-related peptide for migraines: a systematic review with meta-analysis of randomized clinical trials. Int J Mol Sci. 2019;20(14):3527.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"716_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-020-01633-3","volume":"20","author":"H Deng","year":"2020","unstructured":"Deng H, Li G, Nie H, Feng Y, Guo G, Guo W, Tang Z. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine\u2013an updated systematic review and meta-analysis. BMC Neurol. 2020;20(1):1\u201312.","journal-title":"BMC Neurol"},{"key":"716_CR43","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","volume":"81","author":"E Cernuda-Morollon","year":"2013","unstructured":"Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81:1191\u20136.","journal-title":"Neurology"},{"key":"716_CR44","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/0333102410362122","volume":"30","author":"L Edvinsson","year":"2010","unstructured":"Edvinsson L, Chan KY, Eftekhari S, Nilsson E, de Vries R, Saveland H, Dirven CM, Danser AH, Van MaassenDenBrink A. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia. 2010;30:1233\u201340.","journal-title":"Cephalalgia"},{"key":"716_CR45","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2174\/187152707781387314","volume":"6","author":"L Edvinsson","year":"2007","unstructured":"Edvinsson L, Petersen KA. CGRP-receptor antagonism in migraine treatment. CNS Neurol Disord Drug Targets. 2007;6:240\u20136.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"716_CR46","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/sj.bjp.0705807","volume":"142","author":"RJ Storer","year":"2004","unstructured":"Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004;142:1171\u201381.","journal-title":"Br J Pharmacol"},{"key":"716_CR47","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/j.1526-4610.2008.01215.x","volume":"48","author":"PL Durham","year":"2008","unstructured":"Durham PL. Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine. Headache. 2008;48:1269\u201375.","journal-title":"Headache"},{"key":"716_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1526-4610.2012.02262.x","volume":"53","author":"PL Durham","year":"2013","unstructured":"Durham PL, Masterson CG. Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment. Headache. 2013;53:67\u201380.","journal-title":"Headache"},{"key":"716_CR49","doi-asserted-by":"publisher","first-page":"8798","DOI":"10.1523\/JNEUROSCI.1727-09.2009","volume":"29","author":"A Recober","year":"2009","unstructured":"Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J Neurosci. 2009;29:8798\u2013804.","journal-title":"J Neurosci"},{"key":"716_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40263-014-0156-4","volume":"28","author":"ME Bigal","year":"2014","unstructured":"Bigal ME, Walter S. Monoclonal antibodies for migraine: Preventing calcitonin gene-related peptide activity. CNS Drugs. 2014;28:389\u201399.","journal-title":"CNS Drugs"},{"key":"716_CR51","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","volume":"372","author":"TW Ho","year":"2008","unstructured":"Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115\u201323.","journal-title":"Lancet"},{"key":"716_CR52","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/0333102411398399","volume":"31","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, Ho TW. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:712\u201322.","journal-title":"Cephalalgia"},{"key":"716_CR53","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"J Olesen","year":"2004","unstructured":"Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, Group BBCPoCS. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104\u201310.","journal-title":"N Engl J Med"},{"key":"716_CR54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/clpt.2012.198","volume":"93","author":"SD Silberstein","year":"2013","unstructured":"Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther. 2013;93:78\u201385.","journal-title":"Clin Pharmacol Ther"},{"key":"716_CR55","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11940-011-0155-4","volume":"14","author":"J Hoffmann","year":"2012","unstructured":"Hoffmann J, Goadsby PJ. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr Treat Options Neurol. 2012;14:50\u20139.","journal-title":"Curr Treat Options Neurol"},{"key":"716_CR56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","volume":"18","author":"M Deen","year":"2017","unstructured":"Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients-a review of pros and cons. J Headache Pain. 2017;18:96.","journal-title":"J Headache Pain"},{"issue":"11","key":"716_CR57","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1091\u2013100. https:\/\/doi.org\/10.1016\/S1474-4422(15)00245-8.","journal-title":"Lancet Neurol"},{"issue":"9","key":"716_CR58","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13(9):885\u201392. https:\/\/doi.org\/10.1016\/S1474-4422(14)70128-0.","journal-title":"Lancet Neurol"},{"issue":"11","key":"716_CR59","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J, ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100\u20137. https:\/\/doi.org\/10.1016\/S1474-4422(14)70209-1.","journal-title":"Lancet Neurol"},{"issue":"1","key":"716_CR60","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356(1):223\u201331. https:\/\/doi.org\/10.1124\/jpet.115.227793.","journal-title":"J Pharmacol Exp Ther"},{"key":"716_CR61","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548\u201358. https:\/\/doi.org\/10.1038\/clpt.2008.170.","journal-title":"Clin Pharmacol Ther"},{"key":"716_CR62","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/304129a0","volume":"304","author":"MG Rosenfeld","year":"1983","unstructured":"Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue specific RNA processing. Nature. 1983;304:129\u201335.","journal-title":"Nature"},{"key":"716_CR63","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0304-3940(85)90166-1","volume":"58","author":"L Edvinsson","year":"1985","unstructured":"Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett. 1985;58:213\u20137.","journal-title":"Neurosci Lett"},{"key":"716_CR64","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies \u2013 successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338\u201350.","journal-title":"Nat Rev Neurol"},{"key":"716_CR65","doi-asserted-by":"publisher","first-page":"1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:1000097.","journal-title":"PLoS Med"},{"key":"716_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"issue":"10","key":"716_CR67","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"38","author":"M Ashina","year":"2018","unstructured":"Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, Cheng S, Zhang F, Lenz R, Klatt J, Mikol DD. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38(10):1611\u201321. https:\/\/doi.org\/10.1177\/0333102418788347.","journal-title":"Cephalalgia"},{"issue":"10203","key":"716_CR68","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, Janka L, Ashina M. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394(10203):1030\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4.","journal-title":"Lancet"},{"issue":"8","key":"716_CR69","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1177\/0333102419847957","volume":"39","author":"DD Ruff","year":"2019","unstructured":"Ruff DD, Ford JH, Tockhorn-Heidenreich A, Sexson M, Govindan S, Pearlman EM, Wang SJ, Khan A, Aurora SK. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia. 2019;39(8):931\u201344. https:\/\/doi.org\/10.1177\/0333102419847957.","journal-title":"Cephalalgia"},{"issue":"10","key":"716_CR70","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814\u201325. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9.","journal-title":"Lancet Neurol"},{"key":"716_CR71","doi-asserted-by":"publisher","first-page":"101","DOI":"10.23937\/2378-3001\/1410101","volume":"7","author":"K Boldig","year":"2020","unstructured":"Boldig K, Butala N. Migraines and CGRP monoclonal antibodies: a review of cardiovascular side effects and safety profile. Int J Neurol Neurother. 2020;7:101. https:\/\/doi.org\/10.23937\/2378-3001\/1410101.","journal-title":"Int J Neurol Neurother"},{"issue":"1","key":"716_CR72","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6. https:\/\/doi.org\/10.1186\/s10194-018-0955-y.","journal-title":"J Headache Pain"},{"issue":"1","key":"716_CR73","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/brainsci10010030","volume":"10","author":"A Carmine Belin","year":"2020","unstructured":"Carmine Belin A, Ran C, Edvinsson L. Calcitonin gene-related peptide (CGRP) and cluster headache. Brain Sci. 2020;10(1):30. https:\/\/doi.org\/10.3390\/brainsci10010030.","journal-title":"Brain Sci"},{"key":"716_CR74","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S, EARLY Study Group, et al. Long-term (48\u00a0weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache. 2021;61:1351\u201363.","journal-title":"Headache"},{"key":"716_CR75","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Brunelli N, Messina R, et al. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021;22:154.","journal-title":"J Headache Pain"},{"issue":"3","key":"716_CR76","doi-asserted-by":"publisher","first-page":"227","DOI":"10.20344\/amp.11923","volume":"32","author":"H Donato","year":"2019","unstructured":"Donato H, Donato M. Etapas na Condu\u00e7\u00e3o de uma Revis\u00e3o Sistem\u00e1tica. Acta Med Port. 2019;32(3):227\u201335. https:\/\/doi.org\/10.20344\/amp.11923.","journal-title":"Acta Med Port"},{"issue":"1","key":"716_CR77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40779-020-00238-8","volume":"7","author":"LL Ma","year":"2020","unstructured":"Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1):7. https:\/\/doi.org\/10.1186\/s40779-020-00238-8.","journal-title":"Mil Med Res"},{"key":"716_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111557","volume":"139","author":"J Khan","year":"2021","unstructured":"Khan J, Asoom LIA, Sunni AA, Rafique N, Latif R, Saif SA, Almandil NB, Almohazey D, AbdulAzeez S, Borgio JF. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother. 2021;139: 111557. https:\/\/doi.org\/10.1016\/j.biopha.2021.111557.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"716_CR79","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","volume":"17","author":"A Charles","year":"2018","unstructured":"Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174\u201382. https:\/\/doi.org\/10.1016\/S1474-4422(17)30435-0.","journal-title":"Lancet Neurol"},{"issue":"2","key":"716_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2021.705276","volume":"25","author":"TJ Mungoven","year":"2021","unstructured":"Mungoven TJ, Henderson LA, Meylakh N. Chronic migraine pathophysiology and treatment: a review of current perspectives. Front Pain Res (Lausanne). 2021;25(2): 705276. https:\/\/doi.org\/10.3389\/fpain.2021.705276.","journal-title":"Front Pain Res (Lausanne)"},{"issue":"1","key":"716_CR81","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain. 2018;19(1):10. https:\/\/doi.org\/10.1186\/s10194-018-0839-1.","journal-title":"J Headache Pain"},{"issue":"12","key":"716_CR82","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1177\/0333102419856630","volume":"39","author":"V Hoffman","year":"2019","unstructured":"Hoffman V, Xue F, Ezzy SM, Yusuf A, Green E, Eisele O, Kurth T, Seeger JD. Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine receiving prophylactic treatments: an observational cohort study. Cephalalgia. 2019;39(12):1544\u201359. https:\/\/doi.org\/10.1177\/0333102419856630.","journal-title":"Cephalalgia"},{"issue":"11","key":"716_CR83","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/14740338.2021.1948531","volume":"20","author":"F Cheng","year":"2021","unstructured":"Cheng F, Ahmed F. OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation. Expert Opin Drug Saf. 2021;20(11):1275\u201389. https:\/\/doi.org\/10.1080\/14740338.2021.1948531.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"716_CR84","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10194-017-0720-7","volume":"18","author":"A He","year":"2017","unstructured":"He A, Song D, Zhang L, Li C. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain. 2017;18(1):26. https:\/\/doi.org\/10.1186\/s10194-017-0720-7.","journal-title":"J Headache Pain"},{"issue":"1","key":"716_CR85","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22(1):128. https:\/\/doi.org\/10.1186\/s10194-021-01335-2.","journal-title":"J Headache Pain"},{"issue":"19","key":"716_CR86","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383(19):1866\u201376.","journal-title":"N Engl J Med"},{"issue":"3","key":"716_CR87","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3390\/ijerph19031753","volume":"19","author":"J Fern\u00e1ndez-Bravo-Rodrigo","year":"2022","unstructured":"Fern\u00e1ndez-Bravo-Rodrigo J, Pascual-Morena C, Flor-Garc\u00eda A, Saz-Lara A, Sequ\u00ed-Dominguez I, \u00c1lvarez-Bueno C, Barreda-Hern\u00e1ndez D, Cavero-Redondo I. The safety and efficacy of calcitonin gene-related peptide (CGRP) monoclonal antibodies for the preventive treatment of migraine: a protocol for multiple-treatment systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(3):1753. https:\/\/doi.org\/10.3390\/ijerph19031753.","journal-title":"Int J Environ Res Public Health"},{"issue":"34","key":"716_CR88","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e213","volume":"33","author":"HS Kim","year":"2018","unstructured":"Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33(34): e213. https:\/\/doi.org\/10.3346\/jkms.2018.33.e213.","journal-title":"J Korean Med Sci"},{"key":"716_CR89","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","volume":"22","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo VJ, Alpuente A, et al. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain. 2021;22:120. https:\/\/doi.org\/10.1186\/s10194-021-01328-1.","journal-title":"J Headache Pain"},{"issue":"10","key":"716_CR90","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","volume":"268","author":"M Torres-Ferr\u00fas","year":"2021","unstructured":"Torres-Ferr\u00fas M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol. 2021;268(10):3789\u201398. https:\/\/doi.org\/10.1007\/s00415-021-10523-8.","journal-title":"J Neurol"},{"issue":"1","key":"716_CR91","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-021-01323-6","volume":"22","author":"A Scheffler","year":"2021","unstructured":"Scheffler A, Schenk H, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, Holle D. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience. J Headache Pain. 2021;22(1):111. https:\/\/doi.org\/10.1186\/s10194-021-01323-6.","journal-title":"J Headache Pain"},{"key":"716_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01252-4","author":"S Sacco","year":"2021","unstructured":"Sacco S, Lampl C, van MaassendenBrink A, Caponnetto V, Braschinsky M, Ducros A, Little P, Pozo-Rosich P, Reuter U, Ruiz E, de laTorre, Del SanchezRio M, Sinclair AJ, Martelletti P, Katsarava Z, Burden and Attitude to Resistant and Refractory (BARR) Study Group. Burden and attitude to resistant and refractory migraine: a survey from the European headache federation with the endorsement of the European migraine & headache alliance. J Headache Pain. 2021. https:\/\/doi.org\/10.1186\/s10194-021-01252-4.","journal-title":"J Headache Pain"},{"key":"716_CR93","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1007\/s42399-021-00868-6","volume":"3","author":"AG Voloshin","year":"2021","unstructured":"Voloshin AG, Moiseeva IV. Combined interventional treatment of refractory chronic migraine. SN Compr Clin Med. 2021;3:1320\u20136. https:\/\/doi.org\/10.1007\/s42399-021-00868-6.","journal-title":"SN Compr Clin Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00716-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T17:03:29Z","timestamp":1654362209000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00716-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00716-w","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,4]]},"assertion":[{"value":"30 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}